Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview

Research in Developmental Disabilities

Volumn 30, Issue 3, 2009, Pages 572-586

  Matson, Johnny L ^a   Neal, Daniene ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Challenging behaviors; Intellectual disability; Psychotropic

Indexed keywords

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; HUMANS; MENTAL DISORDERS; MENTAL RETARDATION; PATIENT SELECTION; PSYCHOTROPIC DRUGS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 59749093396     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2008.08.007     Document Type: Article

References (109)

1. Aman M.G., De Smedt G., Derivan A., Lyons B., Findling R.L., and The Risperidone Disruptive Behavior Study Group. Double-blind, placebo controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. American Journal of Psychiatry 159 (2002) 1337-1346
2. Aman M.G., Teehan C.J., White A.J., Turbott S.H., and Vaithianathan C. Haloperidol treatment with chronically medicated residents: Dose effects on clinical behavior and reinforcement contingencies. American Journal on Mental Retardation 93 (1989) 452-460
3. Aman M.G., and White A.J. Thioridazine dose effects with reference to stereotypic behavior in mentally retarded residents. Journal of Autism and Developmental Disorders 18 (1988) 355-366
4. Aman M.G., White A.J., and Field C. Chlorpromazine effects on stereotypic and conditioned behavior of severely retarded patients - a pilot study. Journal of Mental Deficiency Research 28 (1984) 253-260
5. Aman M.G., White A.J., Vaithianathan C., and Teehan C.J. Preliminary study of imipramine in profoundly retarded residents. Journal of Autism and Developmental Disabilities 16 (1986) 263-273
6. Amin P., and Yeragani V.K. Control of aggressive and self-mutilative behavior in a mentally retarded patient with lithium. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 32 (1987) 162-163
7. Baumesiter A.A., and Sevin J.A. Psychopharmacologic control of aberrant behavior in the mentally retarded: Toward a more rationale approach. Neuroscience and Biobehavioral Reviews 14 (1990) 253-262
8. Ben Itzchak E., Lahat E., Burgin R., and Zachor A.D. Cognitive behavior and intervention outcome in young children with autism. Research in Developmental Disabilities 29 (2008) 447-458
9. Brahm W.C., Farmer K.C., and Brown R.C. Risperidone for the treatment of fecal smearing in a developmentally disabled adult. American Journal of Health-System Pharmacy 64 (2007) 382-384
10. Bramble D. Psychotropic drug prescribing in child and adolescent learning disability psychiatry. Journal of Psychopharmacology 21 (2007) 486-491
11. Branford D. Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. Journal of Intellectual Disability Research 40 (1996) 322-329
12. Breuning S.E., O'Neill M.J., and Ferguson D.G. Comparison of psychotropic drug, response cost, and psychotropic drug plus response cost procedures for controlling institutionalized mentally retarded persons. Applied Research in Mental Retardation 1 (1980) 253-268
13. Briggs R. Monitoring and evaluating psychotropic drug use for persons with mental retardation: A follow-up report. American Journal on Mental Retardation 93 (1989) 633-639
14. Buitelaar J.K., van der Gaag R.J., Cohen-Kettenis P., and Melman C. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry 62 (2001) 239-248
15. Burk H.W., and Menolascino F.J. Haloperidol in emotionally disturbed mentally retarded individuals. American Journal of Psychiatry 124 (1968) 1589-1591
16. Chadsey-Rusch J., and Sprague R.L. Maladaptive behaviors associated with neuroleptic drug maintenance. American Journal on Mental Retardation 6 (1989) 607-617
17. Cohen I.L., Campbell M., Posner D., Small A.M., Triebel D., and Anderson L.T. Behavioral effects of haloperidol in young autistic children: An objective analysis using a within-subjects reversal design. Journal of the American Academy of Child Psychiatry 19 (1980) 665-677
18. Cohen S.A., Ihrig K., Lott R.S., and Kerrick J.M. Risperidone for aggression and self-injurious behavior in adults with mental retardation. Journal of Autism and Developmental Disorder 28 (1998) 229-233
19. Cohen S.A., and Underwood M.T. The use of clozapine in a mentally retarded and aggressive population. Journal of Clinical Psychiatry 55 (1994) 440-444
20. Cook E.H., Rowlett R., Jaselskis C., and Leventhal B.L. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry 31 (1992) 739-745
21. Craft M., Ismail I.A., Krishnamurti D., Mathews J., Regan A., Seth R.V., et al. Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial. British Journal of Psychiatry 150 (1987) 685-689
22. Crocker A.G., Mercier C., Allaire J.F., and Roy M.E. Profiles and correlates of aggressive behaviour among adults with intellectual disabilities. Journal of Intellectual Disability Research 51 (2007) 786-801
23. Croonenberghs J., Fegert J., Findling R., De Smedt G., Van Dongen S., and The Risperidone Disruptive Behavior Group. Risperidone in children with disruptive behavior disorder and subaverage intelligence: A 1-year, open-label study of 504 patients. Journal of the American Academy of Child and Adolescent Psychiatry 44 (2004) 64-72
24. Dartnall N.A., Holmes J.P., Morgan S.N., and McDougle C.J. Brief report: Two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. Journal of Autism and Developmental Disorders 29 (1999) 87-91
25. Davanzo P.A., Belin T.R., Widowski M.H., and King B.H. Paroxetine treatment of aggression and self-injury in persons with mental retardation. American Journal on Mental Retardation 102 (1998) 427-437
26. Deb S. Medication for behavior problems associated with learning disabilities. Psychiatry 5 (2006) 368-371
27. Dosen A. The developmental psychiatric approach to aggressive behavior among persons with intellectual disabilities. Mental Health Aspects of Developmental Disabilities 7 (2004) 57-66
28. Duggan L., and Brylewski J. Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: A systematic review. Journal of Intellectual Disability Research 43 (1999) 94-104
29. Elliot R.L. Lithium treatment and cognitive changes in two mentally retarded patients. Journal of Nervous and Mental Disease 174 (1986) 689-692
30. Emerson E., and Bromley J. The form and function of challenging behaviours. Journal of Intellectual Disability Research 39 (1995) 388-398
31. Findling R.L., Aman M.G., Eerdekens M., Derivan A., Lyons B., and The Risperidone Disruptive Behavior Study Group. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. American Journal of Psychiatry 161 (2004) 677-684
32. Gagiano C., Read S., Thorpe L., Eerdekens M., and Van Hove I. Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. Psychopharmacology 179 (2005) 629-636
33. Garber H.J., McGonigle J.J., Slomka G.T., and Monteverde E. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. Journal of the American Academy of Child and Adolescent Psychiatry 31 (1992) 1157-1160
34. Ghaziuddin M., Tsai L.Y., and Ghaziuddin N. Hlaoperidol treatment of trichotillomania in a boy with autism and mental retardation. Journal of Autism and Developmental Disorders 21 (1991) 365-371
35. Gothelf D., Goraly O., Avni S., Stawaski M., Hartmann I., Basel-Vanagaite L., et al. Psychiatric morbidity with focus on obsessive-compulsive disorder in an Israeli cohort of adolescents with mild to moderate mental retardation. Journal of Neural Transmission 115 (2008) 1435-1463
36. Haessler F., Glaser T., Beneke M., Pap A.F., Bodenschatz R., and Reis O. Zuclopenthixol in adults with intellectual disabilities and aggressive behaviors. British Journal of Psychiatry 190 (2007) 447-448
37. Hammock R.G., Schroeder S.S., and Levine W.R. The effect of clozapine on self-injurious behavior. Journal of Autism and Developmental Disorders 25 (1995) 611-626
38. Hanzel T.E., Kalachnik J.E., and Harder S.R. A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy. Research in Developmental Disabilities 13 (1992) 381-392
39. Hardan A., Johnson K., Johnson C., and Hrecznyj B. Case study: Risperidone treatment of children and adolescents with developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry 35 (1996) 1551-1556
40. Heistad G.T., Zimmermann R.L., and Doebler M.I. Long-term usefulness of thioridazine for institutionalized mentally retarded patients. American Journal of Mental Deficiency 87 (1982) 243-251
41. Hellings J.A., Zarcone J.R., Reese R.M., Valdpvinos M.G., Marquis J.G., Fleming K.K., et al. A crossover study of risperidone in children, adolescents, and adults with mental retardation. Journal of Autism and Developmental Disorders 36 (2006) 401-411
42. Hill B.K., and Bruininks R.H. Maladaptive behavior of mentally retarded individuals in residential facilities. American Journal of Mental Retardation 88 (1984) 380-387
43. Holden B., and Gitlesen J.P. The relationship between psychiatric symptomotology and motivation of challenging behavior: A preliminary study. Research in Developmental Disabilities 29 (2008) 408-413
44. Horrocks E., and Higbee T.S. An evaluation of a stimulus preference assessment of auditory stimuli for adolescents with developmental disabilities. Research in Developmental Disabilities 29 (2008) 11-20
45. Inoue F. A clinical pharmacy service to reduce psychotropic medication use in an institution for mentally handicapped persons. Mental Retardation 20 (1982) 70-74
46. Janowsky D.S., Kraus J.E., Barnhill J., Elamir B., and Davis J.M. Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disables: An open-label retrospective study. Journal of Clinical Psychopharmacology 23 (2003) 500-504
47. Kaperanovic S., and Simpson G.M. Review of antipsychotics in children and adolescents. Expert Opinion on Pharmacotherapy 7 (2006) 1871-1885
48. Khan B.U. Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. Journal of Autism and Developmental Disorders 27 (1997) 479-489
49. Kiernan, C., Reeves, D., Hatton, C., Alborz, A., Emerson, E., Mason, H., et al. (1997). The HARC challenging behavior project report 1: Persistence and change in the challenging behavior of people with a learning disability. University of Manchester, Manchester: Hester Adrian Research Centre.
50. La Malfa G.P., Castellani A., Bertelli M., and Lassi S. Aggressive behaviours in people with intellectual disabilities: Psychopharmacological treatment. Minerva Psichiatrica 46 (2005) 29-33
51. Lott R.S., Kerrick J.M., and Cohen S.A. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacology Bulletin 32 (1996) 721-729
52. Lowe K., Allen D., Jones E., Brophy S., Moore K., and James W. Challenging behaviours: Prevalence and topographies. Journal of Intellectual Disability Research 51 (2007) 625-636
53. Marshall T. Audit of the use of psychotropic medication for challenging behaviour in a community learning disability service. Psychiatric Bulletin 28 (2004) 447-450
54. Matson J.L. Functional assessment: Applications of methodologies in applied settings. Psychology in Mental Retardation and Developmental Disabilities 32 (2006) 8-10
55. Matson J.L., Bamburg J.W., Mayville E.A., Pinkston J., Bieleck J., Kuhn D., et al. Psychopharmacology and mental retardation: A 10-year review (1990-1999). Research in Developmental Disabilities 21 (2000) 263-296
56. Matson J.L., and Boisjoli J. Multiple versus single maintaining factors of challenging behaviors as assessed by the QABF for adults with intellectual disability (ID). Journal of Intellectual and Developmental Disability 32 (2007) 39-44
57. Matson J.L., and Boisjoli J. Cutoff scores for the Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER) for adults with intellectual disability. Behavior Modification 32 (2008) 109-120
58. Matson J.L., Cooper C., Malone C.J., and Moskow S.L. The relationship of self-injurious behaviors and other maladaptive behaviors among individuals with severe and profound intellectual disability. Research in Developmental Disabilities 29 (2008) 141-148
59. Matson J.L., and Minshawi N.F. Functional assessment of challenging behavior: Toward a strategy for applied settings. Research in Developmental Disabilities 28 (2007) 353-361
60. Matson J.L., Minshawi N.F., Gonzáles M.L., and Mayville S.B. The relationship of comorbid problem behaviors to social skills in persons with profound mental retardation. Behavior Modification 30 (2006) 496-506
61. Matson J.L., and Wilkins J. Antipsychotic drugs for aggression in intellectual disability. The Lancet 371 (2008) 9-10
62. McDougle C.J., Holmes J.P., Carlson D.C., Pelton G.H., Cohen D.J., and Price L.H. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry 55 (1998) 633-641
63. McDougle C.J., Holmes J.P., Bronson M.R., Anderson G.M., Volkmar F.R., Price L.H., et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of the American Academy of Child and Adolescent Psychiatry 36 (1997) 685-693
64. Mikkelsen E.J. Low-dose haloperidol for stereotypic self-injurious behavior in the mentally retarded. New England Journal of Medicine 315 (1986) 398-399
65. Millichamp C.J., and Singh N.N. The effects of intermittent drug therapy on stereotypy and collateral behaviors of mentally retarded persons. Research in Developmental Disabilities 8 (1987) 213-227
66. Myrbakk E., and von Tetzchner S. Psychiatric disorders and behavior problems in people with intellectual disability. Research in Developmental Disabilities 29 (2008) 316-332
67. Nøttestad J.A., and Linaker O.M. Psychotropic drug use among people with intellectual disability before and after deinstitutionalization. Journal of Intellectual Disability Research 47 (2003) 464-471
68. O'Reilly M.F., Sigafoos J., Lancioni G., Rispoli M., Lang R., Chan J., et al. Manipulating the behavior-altering effect of the motivating operation: Examination of the influence on challenging behavior during leisure activities. Research in Developmental Disabilities 29 (2008) 333-340
69. Pary R.J. Discontinuation of neuroleptics in community-dwelling individuals with mental retardation and mental illness. American Journal on Mental Retardation 100 (1995) 207-212
70. Pregelj S., and Barkauskas A. Thioridazine in the treatment of mentally retarded children (a four-year retroactive evaluation). Canadian Psychiatric Association Journal 12 (1967) 213-215
71. Radouco-Thomas M., Bolduc M., Brisson A., Brassard P., Fortier L., and Thivierge J. Pilot study on the use of psychotropic medication in persons with mental retardation. Progress in Neuro-Psychopharmacology and Biological Psychiatry 28 (2004) 879-883
72. Reyes M., Croonenberghs J., Augustyns I., and Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. Journal of Child and Adolescent Psychopharmacology 16 (2006) 260-272
73. Ricketts R.W., Goza A.B., Ellis C.R., Singh Y.N., Chambers S., Singh N.N., et al. Clinical effects of buspirone on intractable self-injury in adults with mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry 33 (1994) 270-276
74. Ricketts R.W., Goza A.B., Ellis C.R., Singh Y.N., Singh N.N., and Cooke J.C. Fluoxetine treatment of severe self-injury in young adults with mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry 32 (1993) 865-869
75. Ringdahl J.E., Call N.A., Meus J.B., Boelter E.W., and Christensen T.J. Assessment and treatment of aggressive behavior without a clear social function. Research in Developmental Disabilities 29 (2008) 351-362
76. Santosh P.J., and Baird G. Psychopharmacology in children and adults with intellectual disability. Lancet 354 (1999) 231-240
77. Shireman T.I., Reichard A., and Rigler S.K. Psychotropic medication use among Kansas medicaid youths with disabilities. Journal of Child and Adolescent Psychopharmacology 15 (2005) 107-115
78. Simon E.W., Blubaugh K.M., and Pippidis M. Substituting traditional antipsychotics with risperidone for individuals with mental retardation. Mental Retardation 34 (1996) 359-366
79. Singh A.N., Matson J.L., Cooper C.L., Dixon D., and Sturmey P. The use of risperidone among individuals with mental retardation: Clinically supported or not?. Research in Developmental Disabilities 26 (2005) 203-218
80. Singh I., and Owino W.J.E. Double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behaviour disorders. Journal of Intellectual Disability Research 36 (1992) 541-549
81. Singh N.N., and Aman M.G. Effects of Thioridazine dosage on the behavior of severely mentally retarded persons. American Journal of Mental Deficiency 85 (1981) 580-587
82. Snyder R., Turgay A., Aman M., Binder C., Fisman S., Carroll A., and The Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry 41 (2002) 1026-1036
83. Sovner R., and Hurley A. The management of chronic behavior disorders in mentally retarded adults with lithium carbonate. Journal of Nervous and Mental Disease 169 (1981) 191-195
84. Sprague R.L., and Werry J.S. Methodology of Psychopharmacological studies with the retarded. In: Ellis N.R. (Ed). International review of research in mental retardation (1971), Academic Press, New York 147-219
85. Spreat S., Behar D., Reneski B., and Miazzo P. Lithium carbonate for aggression mentally retarded persons. Comprehensive Psychiatry 30 (1989) 505-511
86. Spreat S., and Conroy J. Use of psychotropic medications for persons with mental retardation who live in Oklahoma nursing homes. Psychiatric Services 49 (1998) 510-512
87. Spreat S., Conroy J.W., and Fullerton A. Statewide longitudinal survey of psychotropic medication use for persons with mental retardation: 1994 to 2000. American Journal on Mental Retardation 109 (2004) 322-331
88. Spreat S., Conroy J.W., and Jones J. Use of psychotropic medication in Oklahoma: A statewide survey. American Journal on Mental Retardation 102 (1997) 80-85
89. Spivak B., Mozes T., Mester R., Kodelik M., and Weizman A. Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: An open label study. Journal of Child and Adolescent Psychopharmacology 11 (2001) 279-284
90. Stolker J.J., Koedoot P.J., Heerdick E.R., Leufkens H.G.M., and Nolen W.A. Psychotropic drug use in intellectually disabled group-home residents with behavioural problems. Pharmacopsychiatry 35 (2002) 19-23
91. Stolker J.J., Koedoot P.J., Heerdink E.R., Leufkens H.G.M., and Nolen W.A. Psychotropic drug use by mentally retarded persons with behavioural problems residing in care homes. Tijdschrift voor Psychiatrie 45 (2003) 667-676
92. Stone R.K., Alvarez W.F., Ellman G., Hom A.C., and White J.F. Prevalence and prediction of psychotropic drug use in California developmental centers. American Journal on Mental Retardation 93 (1989) 627-632
93. Su C.Y., Lin Y.H., Wu Y.Y., and Chen C.C. The role of cognition and adaptive behavior in employment of people with mental retardation. Research in Developmental Disabilities 29 (2008) 83-95
94. Suresh T. 'A's required' neuroleptics: Have these drugs a place in the management of challenging behavior in intellectual disability?. Journal of Intellectual Disability Research 42 (1998) 500-504
95. Szymanski L., Madow L., Mallory G., Menolascino F.J., Pace L., and Eidelman S. Report of the APA task force on services to adults with mental retardation and developmental disabilities (1991), American Psychiatric Press, Washington, DC
96. Taracena D.L., and Rada M. Psychoactive drug use in mentally retarded patients. Anales de Psiquiatria 18 (2002) 35-45
97. Tarjan L., Lowery V.E., and Wright S.W. Use of chlorpromazine in 278 mentally deficient patients. American Medical Association: Journal of Disturbed Children 94 (1957) 294-300
98. Taylor J.L., Novaco R.W., Gilmer B.T., Robertson A., and Thorne I. Individual cognitive-behavioural anger treatment for people with mild-borderline intellectual disabilities and histories of aggression: A controlled trial. British Journal of Clinical Psychology 44 (2005) 367-382
99. Thompson T., and Caruso M. Epidemiology of self-injurious behavior in mental retardation: A review. In: Schroeder S.P., Oster-Granite M.L., and Thompson T. (Eds). Self-injurious behavior: Gene-brain-behavior relationships (2002), American Psychological Association, Washington, DC 41-77
100. Trosi A., Vicario E., Nuccetelli F., Ciani N., and Pasini A. Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation. Pharmacopsychiatry 28 (1995) 73-76
101. Turgay A., Binder C., Snyder R., and Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQ's. Pediatrics 110 (2002) e34
102. Tyrer P., Oliver-Africano P.C., Ahmed Z., Bouras N., Cooray S., Deb S., et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behavior in patients with intellectual disability: A randomised controlled trial. The Lancet 371 (2008) 57-63
103. Tyrer S.P., Walsh A., Edwards D.E., Berney T., and Stephens D.A. Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry 8 (1984) 751-755
104. Vanden Borre R., Vermote R., Buttiens M., Thiry P., Dierick G., Geutjens J., et al. Risperidone as add-on therapy in behavioural disturbances in mental retardation: A double-blind placebo-controlled cross-over study. Acta Psychiatrica Scandinavica 87 (1993) 167-171
105. Verhoeven W.M.A., and Tuinier S. The effect of buspirone on challenging behaviour in mentally retarded patients: An open prospective multiple-case study. Journal of Intellectual Disability Research 40 (1996) 502-508
106. Verhoeven W.M.A., and Tuinier S. Pharmacotherapy in people with learning disabilities: A dimensional approach. Tijdschrift voor Psychiatrie 41 (1999) 219-231
107. Williams H., Clarke R., Bouras W., Martin J., and Holt G. Use of the atypical antipsychotic olanzapine and risperidone in adults with intellectual disability. Journal of Intellectual Disability Research 44 (2000) 164-169
108. Zarcone J.R., Lindauer S.E., Morse P.S., Crosland K.A., Valdovines M.G., McKerchar T.L., et al. Effects of Risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. American Journal on Mental Retardation 109 (2004) 310-321
109. Zuddas A., Ledda M.G., Frata A., Muglia P., and Cianchetti C. Clinical effects of clozapine on autistic disorder. American Journal of Psychiatry 153 (1996) 5